Protection of Astragalus Polysaccharides and Codonopsis Pilosula Polysaccharides on Alveolar Macrophage Phagocytosis of Chronic Obstructive Pulmonary Disease Mice With PM2.5 Inhalation

SESSION TITLE: COPD II SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: To investigate the possible protection of Astragalus polysaccharides (APS) and Codonopsis Pilosula polysaccharides (CPP) extracted from two traditional Chinese medicine on alveolar macrophage (AM) phagocytosis and local and systemic inflammation in chronic obstructive pulmonary disease (COPD) mice with long-time fine particulate matter with a mean aerodynamic diameter ≤2.5 μm (PM2.5) inhalation. METHODS: Cigarette smoke exposure was used to establish the COPD mice models and PM2.5 inhalation were performed in the meantime following dosage of 770μg/m3. APS and CPP were orally administrated at the dose of 200mg/kg and 300mg/kg. Mice peak inspiratory flow (PIF) and peak expiratory flow (PEF) were measured by mice noninvasive body plethysmograph and lung histopathology was observed. AMs were isolated from lung tissue by discontinuous density gradient centrifugation. Mean fluorescence intensity (MFI) and the ability of AM phagocytosed flurescein isothiocyanate-labeled Escherichia coli (FITC-E.coli) (AM %) were detected by flow cytometry respectively. Levels of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF) alpha in bronchoalveolar lavage fluid (BALF) and serum were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: COPD mice performed defective alveolar macrophage phagocytosis of FITC-E.coli and increased levels of IL-6, IL-8 and TNF-α in local lung and serum. PIF and PEF were significantly decreased and small airway inflammation and emphysema were detected in COPD mice after cigarette smoke exposure. Meanwhile, PM2.5 inhalation aggravate the damages above. But with APS and CPP gavage, the damages were retrieved both in the COPD mice and COPD mice with PM2.5 inhalation. CONCLUSIONS: APS and CPP could reinforce AM phagocytosis and retrieve defective resolution of pulmonary and systmetic inflammation in COPD mice with/without PM2.5 inhalation. CLINICAL IMPLICATIONS: Astragalus polysaccharides and Codonopsis pilosula polysaccharides could be used to protect COPD patients suffered from air pollution. DISCLOSURE: Xu Chu: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China Xiaoju Liu: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China Jingman Qiu: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China Xiaoli Zeng: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China Hairong Bao: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China Juan Shu: Grant monies (from sources other than industry): Gansu Provincial Traditional Chinese Medicine Science and Technology Research Subject (GZK-2012-25), China, Grant monies (from sources other than industry): Gansu Provincial Technology Support Program (144FKCA062), China No Product/Research Disclosure Information